Background: Brain metastases (BMs) from endometrial cancer (EC) are rare and challenging to treat, with limited standardized guidelines. This systematic review aims to evaluate the incidence, therapeutic strategies, and outcomes associated with brain metastases in EC patients, offering insights for clinical practice and future research. Methods: A comprehensive literature search was conducted using PRISMA guidelines, including PUBMED up to October 2024. Reports reporting individual or aggregate data on EC brain metastases were included. Descriptive and quantitative analyses were performed on incidence, treatment modalities, and survival outcomes. Three reports that used data from the Surveillance, Epidemiology, and End Results and National Cancer Database were used only to assess the incidence of brain metastases from endometrial carcinoma. Results: From 911 reports identified, we included 99 reports, identifying 594 cases; these and the case of a patient with brain metastasis from endometrial carcinoma followed at our center were used for analysis of disease characteristics; incidence; and treatment modalities, such as surgery, radiotherapy, chemotherapy, and combinations. Survival outcomes were influenced by treatment type and disease characteristics, with multimodal approaches showing improved outcomes. Discussion: This review underscores the rarity of EC brain metastases and highlights the need for tailored, multimodal treatment strategies. Future research should focus on prospective trials and molecular profiling to optimize management.
背景：子宫内膜癌（EC）脑转移较为罕见且治疗困难，目前缺乏标准化的诊疗指南。本系统性综述旨在评估子宫内膜癌患者脑转移的发生率、治疗策略及预后，为临床实践和未来研究提供参考。 方法：遵循PRISMA指南，对截至2024年10月的PUBMED数据库进行系统性文献检索，纳入包含子宫内膜癌脑转移个体或汇总数据的研究报告。对脑转移发生率、治疗方式及生存结局进行描述性与定量分析。其中三篇基于美国监测、流行病学和最终结果数据库及国家癌症数据库的研究仅用于评估子宫内膜癌脑转移的发生率。 结果：从911篇文献中筛选出99篇符合条件的研究，共纳入594例病例；结合本中心收治的1例子宫内膜癌脑转移患者，对疾病特征、发生率及手术、放疗、化疗等治疗方式进行分析。生存结局受治疗方式和疾病特征影响，多模式联合治疗显示出更好的预后。 讨论：本综述揭示了子宫内膜癌脑转移的罕见性，强调需要个体化、多模式综合治疗策略。未来研究应聚焦前瞻性临床试验及分子特征分析，以优化临床管理。
肿瘤(癌症)患者之家